1 option
CADTH Canadian Drug Expert Committee recommendation : indication : for the treatment of amyotrophic lateral sclerosis. Edaravone (Radicava -- Mitsubishi Tanabe Pharma Corporation) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Endosomes.
- Survivalism.
- Physical Description:
- 1 online resource (8 pages) : illustrations
- Edition:
- Final.
- Place of Publication:
- Ottawa (ON) : CADTH, 2019.
- Summary:
- Edaravone has a Health Canada indication for the treatment of ALS. Edaravone is a free radical scavenger. It is available as 30 mg edaravone in a 100 mL isotonic, sterile, aqueous solution and the Health Canada-approved dose is an intravenous infusion of 60 mg administered over a 60-minute period according to the following schedule: an initial treatment cycle with daily doses for 14 days, followed by a 14-day drug-free period; subsequent treatment cycles with daily doses for 10 days out of a 14-day period, followed by 14-day drug-free periods.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.